Table 5

Multivariate Cox model (DFS) including interaction of uPA/PAI-1 with adjuvant treatment in breast cancer patients with zero to three involved axillary nodes (n = 2592)a

Analysis was stratified by the Center: 50 patients were censored before the first event in the stratum, 800 events total. Stages of analysis are as in Table 3 <$REFLINK> .

Significant factorsbCoding for interpretation of βFinal model
PβHRc (95% CI)
Involved lymph nodesFractional rank<0.0012.37
 1 node vs. node-negative2.10 (1.8–2.4)d
2 nodes vs. node-negative2.70 (2.2–3.3)d
 3 nodes vs. node-negative3.19 (2.5–4.0)d
AgeSquared fractional rank<0.0011.876.48 (2.52–16.66)
Fractional rank<0.001−2.630.07 (0.03–0.19)
Tumor stageRest (1) vs. pT1 (0)<0.0010.351.42 (1.23–1.65)
PgRFractional rank<0.001−0.580.56 (0.42–0.75)
ERFractional rank0.0080.431.53 (1.12–2.10)
uPA/PAI-1High (1) vs. low (0)<0.0010.792.21 (1.88–2.59)
Adjuvant chemotherapyYes (1) vs. no (0)0.034−0.330.72 (0.53–0.98)
Adjuvant endocrine therapyYes (1) vs. no (0)0.005−0.410.66 (0.48–0.90)
Interaction, chemotherapy × uPA/PAI-1Both 1 vs. either or both 00.041−0.360.70 (0.50–0.98)
  • a One of 2593 was excluded because of missing information on adjuvant chemotherapy.

  • b Coding of variables as reported in “Materials and Methods.”

  • c Hazard for fractional rank = 1 compared with fractional rank = 0.

  • d HR for patients with 1, 2, and 3 positive nodes compared with node negative patients, CI is approximate because of fractional ranks.